Palo Santo on investing in 2nd gen psychedelics and public markets
Mar 21, 2022
48:20
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
In today’s episode, we chat with Tim Schlidt, a partner at Palo Santo. Palo Santo is a fund investing in psychedelic therapeutics. Palo Santo’s portfolio includes companies like Eleusis, Tactogen, and Journey Clinical.
In this episode, we discuss:
Tim’s background in healthcare finance
Investing in classic psychedelic compounds vs. 2nd generation compounds
Hallmarks of a good first meeting with a prospective investment
